$0.26 EPS Expected for Live Oak Bancshares, Inc. (LOB); 18 Analysts Are Bullish Celgene (CELG) Last Week

January 19, 2018 - By Adrian Erickson

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by SunTrust given on Friday, December 22. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, October 19. The stock of Celgene Corporation (NASDAQ:CELG) has “Neutral” rating given on Friday, October 27 by Cantor Fitzgerald. The firm has “Buy” rating by SunTrust given on Monday, January 8. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Canaccord Genuity on Tuesday, June 6. The rating was initiated by Raymond James on Tuesday, September 1 with “Strong-Buy”. The company was maintained on Friday, July 28 by Leerink Swann. On Thursday, July 6 the stock rating was maintained by Oppenheimer with “Buy”. The firm has “Buy” rating given on Friday, April 29 by Suntrust Robinson. See Celgene Corporation (NASDAQ:CELG) latest ratings:

08/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $130.0 Maintain
08/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $147.0 Maintain
08/01/2018 Broker: Credit Suisse Rating: Buy New Target: $125.0 Maintain
08/01/2018 Broker: SunTrust Rating: Buy New Target: $127.0 Maintain
08/01/2018 Broker: Deutsche Bank Rating: Hold New Target: $110.0
05/01/2018 Broker: Bank of America Rating: Hold New Target: $120.0 Downgrade
27/12/2017 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Old Target: $162 Downgrade
22/12/2017 Broker: SunTrust Rating: Buy New Target: $127.0 Maintain
21/12/2017 Broker: Guggenheim Rating: Buy New Target: $152.0 Maintain
21/12/2017 Broker: Piper Jaffray Rating: Hold New Target: $100.0 Maintain

Analysts expect Live Oak Bancshares, Inc. (NASDAQ:LOB) to report $0.26 EPS on January, 24.They anticipate $0.09 EPS change or 52.94% from last quarter’s $0.17 EPS. LOB’s profit would be $10.37M giving it 22.88 P/E if the $0.26 EPS is correct. After having $0.34 EPS previously, Live Oak Bancshares, Inc.’s analysts see -23.53% EPS growth. The stock decreased 1.86% or $0.45 during the last trading session, reaching $23.8. About 39,138 shares traded. Live Oak Bancshares, Inc. (NASDAQ:LOB) has risen 55.47% since January 19, 2017 and is uptrending. It has outperformed by 38.77% the S&P500.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It fall, as 44 investors sold Celgene Corporation shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Northstar Gru owns 2,608 shares. Alphamark Advisors Limited Liability reported 72 shares. Boston invested in 197,816 shares. Cleararc Cap owns 17,732 shares. Private Trust Communication Na has 0.46% invested in Celgene Corporation (NASDAQ:CELG). 13,751 were reported by Cetera Advisor Networks Limited Company. Moreover, Cetera Advisors Ltd has 0.21% invested in Celgene Corporation (NASDAQ:CELG) for 23,526 shares. Whalerock Point Prtn Ltd Com holds 1.22% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 23,780 shares. Tarbox Family Office owns 0.09% invested in Celgene Corporation (NASDAQ:CELG) for 1,348 shares. 2,117 are held by Americafirst Capital Mgmt Ltd Co. At Savings Bank has 22,237 shares. Wendell David Assocs Inc has 92,735 shares. Blackhill Cap accumulated 0.68% or 24,800 shares. Deutsche Bank & Trust Ag has invested 0.64% in Celgene Corporation (NASDAQ:CELG). Altfest L J & Co has 0.29% invested in Celgene Corporation (NASDAQ:CELG) for 4,113 shares.

Since August 2, 2017, it had 0 insider purchases, and 5 selling transactions for $6.27 million activity. $1.01 million worth of stock was sold by KAPLAN GILLA on Wednesday, August 2. MARIO ERNEST also sold $2.42M worth of Celgene Corporation (NASDAQ:CELG) on Thursday, August 10. Curran Terrie had sold 1,727 shares worth $248,498 on Monday, September 25. CASEY MICHAEL D had sold 9,250 shares worth $1.29M on Tuesday, September 5.

The stock decreased 0.29% or $0.3 during the last trading session, reaching $101.72. About 9.28 million shares traded or 8.30% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 19, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $80.09 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 23.84 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Live Oak Bancshares, Inc. operates as the bank holding firm for the Live Oak Banking Company that provides various commercial banking services and products to individuals and businesses in North Carolina. The company has market cap of $949.07 million. The firm accepts various deposit products. It has a 25.51 P/E ratio. It also offers loans comprising small business administration loans; commercial and industrial loans; construction and development loans; owner occupied and non-owner occupied commercial real estate loans; and commercial land loans.

Among 6 analysts covering Live Oak Bancshares (NASDAQ:LOB), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Live Oak Bancshares has $29.0 highest and $1 lowest target. $25.80’s average target is 8.40% above currents $23.8 stock price. Live Oak Bancshares had 13 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by Sandler O’Neill on Thursday, January 4 with “Buy”. The rating was initiated by Sandler O’Neill with “Hold” on Monday, August 17. The stock has “Buy” rating by SunTrust on Tuesday, November 28. The stock of Live Oak Bancshares, Inc. (NASDAQ:LOB) has “Outperform” rating given on Monday, August 17 by Bruyette & Woods”. Keefe Bruyette & Woods initiated Live Oak Bancshares, Inc. (NASDAQ:LOB) on Monday, October 16 with “Hold” rating. KBW initiated it with “Outperform” rating and $24 target in Monday, August 17 report. The stock has “Buy” rating by Suntrust Robinson on Friday, January 29. On Friday, November 6 the stock rating was upgraded by Sandler O’Neill to “Buy”. Sandler O’Neill upgraded the stock to “Buy” rating in Wednesday, September 6 report. The rating was initiated by SunTrust with “Neutral” on Monday, August 17.